Research Results from Massachusetts General Hospital Update Understanding of Type 2 Diabetes (Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin).

A recent study conducted at Massachusetts General Hospital compared the risk of gout and recurrent flares between patients with type 2 diabetes (T2D) who were prescribed sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and those who were prescribed sulfonylureas. The study found that patients who initiated SGLT2i had a lower incidence of gout compared to those who initiated sulfonylureas. SGLT2i use was also associated with fewer recurrent flares among patients with gout and a lower risk of major adverse cardiovascular events. These findings suggest that SGLT2i may be a beneficial treatment option for patients with T2D who are at risk for or already have gout. [Extracted from the article]